maternal embryonic leucine zipper kinase

OTSSP167 (OTS167) is an orally available inhibitor of maternal embryonic leucine zipper kinase (MELK) with potential antineoplastic activity.

MELK-IN-1 (MELK inhibitor 17) is a potent inhibitor of maternal embryonic leucine zipper kinase (MELK),(IC50:3nm;Ki:0.39 nM).

HTH-01-091 is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor (IC50: 10.5 nM) that also inhibits PIM1 2 3, RIPK2, DYRK3, smMLCK, and CLK2. It can be used to study breast cancer.

MELK-8a hydrochloride is a potent inhibitor of maternal embryonic leucine zipper kinase (MELK, IC50 = 2 nM). 

OTSSP167 hydrochloride is a highly potent inhibitor of MELK(IC50 : 0.41 nM).

MELK-8a (NVS-MELK8a) is a potent and selective inhibitor of maternal embryonic leucine zipper kinase (MELK), with an IC50 of 2 nM and an IC50 of 0.42 μM in cellular assays. MELK is crucial in regulating mitosis in cancer cells.

BX-795 hydrochloride is a TBK1 and IKKε inhibitor. BX-795 is a potential maternal embryonic leucine zipper kinase inhibitor.

HTH-01-091 TFA, a potent and selective inhibitor of maternal embryonic leucine zipper kinase (MELK), exhibits an IC50 of 10.5 nM. Besides its primary target, it also inhibits PIM1 2 3, RIPK2, DYRK3, smMLCK, and CLK2, positioning it as a promising agent for breast cancer research [1].